Global Interventional Cardiology Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Interventional Cardiology Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Jul 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Global Interventional Cardiology Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the Global Interventional Cardiology Market size in 2022 - 14.61 and 2030 - 23.61, highlighting the projected market growth. USD 14.61 Billion USD 23.61 Billion 2022 2030
Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 14.61 Billion
Diagram Market Size (Forecast Year)
USD 23.61 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • ABIOMEDInc.
  • ACIST Medical Systems
  • B. Braun Melsungen AG
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation

Global Interventional Cardiology Market, By Device Type (Conventional Device, Advanced Device), End User (Hospitals, Clinics, Cardiac Catheterization Laboratories, Ambulatory Surgical Centres, Others) - Industry Trends and Forecast to 2030.

Interventional Cardiology Market

Interventional Cardiology Market Analysis and Size

The increasing prevalence of cardiovascular diseases and technological advancements have significantly improved the design and functionality of the interventional cardiology market and have carved the way for market growth. In addition, the rising healthcare expenditure and the increasing geriatric population contribute to the market growth.

Data Bridge Market Research analyzes that the global interventional cardiology market, which was USD 14.61 billion in 2022, would rocket up to USD 23.61 billion by 2030, and is expected to undergo a CAGR of 7.1% during the forecast period. This indicates that the conventional device segment dominates the device type segment of the market owing to the advancements in technology that have led to the development of advancements in interventional cardiology for various use.

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Interventional Cardiology Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2030)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

By Device Type (Conventional Device, Advanced Device), End User (Hospitals, Clinics, Cardiac Catheterization Laboratories, Ambulatory Surgical Centres, Others)

Countries Covered

U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, and Rest of Middle East and Africa

Market Players Covered

ABIOMED, Inc. (U.S.), ACIST Medical Systems (U.S.), B. Braun Melsungen AG (U.S.), Biotronik SE & Co. KG (Germany), Boston Scientific Corporation (U.S.), BD (U.S.), Cook (U.S.), Cardinal Health (U.S.), Edwards Lifesciences Corporation (U.S.), Ivascular (Spain), S.L.U. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), Merit Medical Systems (U.S.), Koninklijke Philips N.V. (U.S.), Abbott (U.S.), Terumo Corporation (Japan), Rontis Corporation (Switzerland), W. L. Gore & Associates, Inc. (U.S.), Biosensors International Group, Ltd. (U.S.), and GENERAL ELECTRIC COMPANY (U.S.) among others

Market Opportunities

  • Increasing healthcare expenditure
  • Growing elderly population

Market Definition

Interventional cardiology is a branch of cardiology that focuses on diagnosing and treating cardiovascular diseases using minimally invasive techniques. The global interventional cardiology market refers to the worldwide market for medical devices and procedures used in interventional cardiology. Physicians use catheters (thin, flexible tubes) and other medical devices in interventional cardiology to access and treat the heart and blood vessels. These procedures are typically performed through small incisions or punctures in the skin rather than through open surgery, which helps reduce risks, complications, and recovery time for patients.

Global Interventional Cardiology Market Dynamics

Drivers

  • Increasing prevalence of cardiovascular diseases

The rising incidence of cardiovascular diseases, such as coronary artery disease, heart attacks, and cardiac arrhythmias, is a major driver for market growth. The need for effective diagnosis and treatment of these conditions has led to the growth in demand for interventional cardiology procedures.

  • Preference for minimally invasive procedures

Interventional cardiology procedures are minimally invasive, meaning they involve smaller incisions and have shorter recovery times compared to traditional open-heart surgeries. As patients and physicians increasingly prefer minimally invasive procedures, the demand for interventional cardiology is expected to rise.

  • Technological advancements

Advances in interventional cardiology technologies and techniques have greatly improved the outcomes of cardiac procedures. Innovations such as drug-eluting stents, bioresorbable stents, and Transcatheter Aortic Valve Replacement (TAVR) have revolutionized the field, attracting both patients and healthcare providers to interventional cardiology procedures.

Opportunities

  • Increasing healthcare expenditure

Increased healthcare spending, particularly in developing countries, has led to improved access to advanced cardiac care, including interventional cardiology. As governments and healthcare organizations invest in upgrading medical infrastructure and facilities, the interventional cardiology market is likely to expand.

  • Growing elderly population

The global population is aging, and elderly individuals are more susceptible to cardiovascular diseases. With the increasing aging population, there is a higher demand for interventional cardiology procedures to diagnose and treat cardiac conditions in this group, driving the market growth.

Restraint

  • High cost of interventional procedures

Interventional cardiology procedures, such as angioplasty and stenting, can be costly. The high cost can limit access to these procedures in developing countries and create financial burdens for patients and healthcare systems in general.

Challenge

  • Stringent regulatory approval processes

The development and commercialization of interventional cardiology devices require extensive clinical trials and regulatory approvals. Stringent regulatory processes can significantly delay the introduction of new devices and technologies to the market, affecting the growth potential of the industry.

This global interventional cardiology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on this market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Recent Developments

  • In May 2023, Abbott announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations
  • In May 2022, Babson Diagnostics, a science-first healthcare technology company, and BD, a leading global medical technology company, announced the expansion of a strategic partnership to move blood sample collection into new care settings, including enabling patients to collect blood samples at home for diagnostic testing.

Global Interventional Cardiology Market Scope

The global interventional cardiology market is segmented into two notable segments based on device type and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Device Type

  • Conventional Device
  • Advanced Device

End User

  • Hospitals
  • Clinics
  • Cardiac Catheterization Laboratories
  • Ambulatory Surgical Centres
  • Others

Global Interventional Cardiology Market Regional Analysis/Insights

The global interventional cardiology market is analysed and market size insights and trends are provided by device type and end user as referenced above.

The countries covered in this market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.

North America dominates the global interventional cardiology market due to the presence of major key players, high disposable income, high healthcare expenditure, and a well-developed healthcare sector in this region.

Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to increasing R&D activities, rising investment in the healthcare sector, and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global interventional cardiology market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2015-2020.

Competitive Landscape and Global Interventional Cardiology Market Share Analysis

The global interventional cardiology market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to market .

Some of the major players operating in the global interventional cardiology market  are:

  • ABIOMED, Inc. (U.S.)
  • ACIST Medical Systems (U.S.)
  • B. Braun Melsungen AG (U.S.)
  • Biotronik SE & Co. KG (Germany)
  • Boston Scientific Corporation (U.S.)
  • BD (U.S.)
  • Cook (U.S.)
  • Cardinal Health (U.S.)
  • Edwards Lifesciences Corporation (U.S.)
  • Ivascular (Spain)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Medtronic (U.S.)
  • Merit Medical Systems (U.S.)
  • Koninklijke Philips N.V. (U.S.)
  • Abbott (U.S.)
  • Terumo Corporation (Japan)
  • Rontis Corporation (Switzerland)
  • W. L. Gore & Associates, Inc. (U.S.)
  • Biosensors International Group, Ltd. (U.S.)
  • GENERAL ELECTRIC COMPANY (U.S.)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1. INTRODUCTION

 

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL INTERVENTIONAL CARDIOLOGY MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

 

2. MARKET SEGMENTATION

 

2.1 KEY TAKEAWAYS

 

2.2 ARRIVING AT THE GLOBAL INTERVENTIONAL CARDIOLOGY MARKET SIZE

 

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS 

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 SALES DATA VOLUME

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

 

2.3 GLOBAL INTERVENTIONAL CARDIOLOGY MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

 

3. MARKET OVERVIEW

 

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

 

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

 

5.1 PESTEL ANALYSIS

5.2 PORTER’S 5 FORCES MODEL

5.3 STRATEGIC INITIATIVES

 

6. REGULATORY FRAMWORK

 

7. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY PRODUCT

 

7.1 OVERVIEW

(NOTE: MARKET VALUE, VOLUME AND ASP ANALYSIS WOULD BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS OF PRODUCT)

 

7.2 GUIDE WIRES

 

7.2.1 CORONARY GUIDE WIRES

 

7.2.1.1. MARKET VALUE (USD MILLION)

7.2.1.2. MARKET VALUE (UNITS)

7.2.1.3. AVERAGE SELLING PRICE (USD)

 

7.2.2 SPECIALTY GUIDE WIRES

 

7.2.2.1. MARKET VALUE (USD MILLION)

7.2.2.2. MARKET VALUE (UNITS)

7.2.2.3. AVERAGE SELLING PRICE (USD)

 

7.3 CATHETERS

 

7.3.1 BALLOON DILATATION CATHETERS

 

7.3.1.1. MARKET VALUE (USD MILLION)

7.3.1.2. MARKET VALUE (UNITS)

7.3.1.3. AVERAGE SELLING PRICE (USD)

 

7.3.2 ANGIOGRAPHY CATHETERS

 

7.3.2.1. MARKET VALUE (USD MILLION)

7.3.2.2. MARKET VALUE (UNITS)

7.3.2.3. AVERAGE SELLING PRICE (USD)

 

7.3.3 INTRAVASCULAR ULTRASOUND (IVUS) CATHETERS

 

7.3.3.1. MARKET VALUE (USD MILLION)

7.3.3.2. MARKET VALUE (UNITS)

7.3.3.3. AVERAGE SELLING PRICE (USD)

 

7.3.4 PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY (PTCA) GUIDING CATHETERS

 

7.3.4.1. MARKET VALUE (USD MILLION)

7.3.4.2. MARKET VALUE (UNITS)

7.3.4.3. AVERAGE SELLING PRICE (USD)

7.3.5 GUIDE EXTENSION CATHETERS

 

7.3.5.1. MARKET VALUE (USD MILLION)

7.3.5.2. MARKET VALUE (UNITS)

7.3.5.3. AVERAGE SELLING PRICE (USD)

 

7.3.6 MICROCATHETERS

 

7.3.6.1. MARKET VALUE (USD MILLION)

7.3.6.2. MARKET VALUE (UNITS)

7.3.6.3. AVERAGE SELLING PRICE (USD)

 

7.3.7 DUAL LUMEN CATHETERS

 

7.3.7.1. MARKET VALUE (USD MILLION)

7.3.7.2. MARKET VALUE (UNITS)

7.3.7.3. AVERAGE SELLING PRICE (USD)

 

7.3.8 OTHERS

 

7.4 CORONARY STENTS

 

7.4.1 BY TYPE

 

7.4.1.1. BARE STENTS

 

7.4.1.1.1. MARKET VALUE (USD MILLION)

7.4.1.1.2. MARKET VALUE (UNITS)

7.4.1.1.3. AVERAGE SELLING PRICE (USD)

 

7.4.1.2. DRUG-ELUTING STENTS

 

7.4.1.2.1. BIODEGRADABLE

 

7.4.1.2.1.1 MARKET VALUE (USD MILLION)

7.4.1.2.1.2 MARKET VALUE (UNITS)

7.4.1.2.1.3 AVERAGE SELLING PRICE (USD)

 

7.4.1.2.2. NON-BIODEGRADABLE

 

7.4.1.2.2.1 MARKET VALUE (USD MILLION)

7.4.1.2.2.2 MARKET VALUE (UNITS)

7.4.1.2.2.3 AVERAGE SELLING PRICE (USD)

 

7.4.1.3. BIOENGINEERED STENTS

 

7.4.1.3.1. MARKET VALUE (USD MILLION)

7.4.1.3.2. MARKET VALUE (UNITS)

7.4.1.3.3. AVERAGE SELLING PRICE (USD)

 

7.4.1.4. DUAL THERAPY STENTS

 

7.4.1.4.1. MARKET VALUE (USD MILLION)

7.4.1.4.2. MARKET VALUE (UNITS)

7.4.1.4.3. AVERAGE SELLING PRICE (USD)

7.4.2 BY MATERIAL

 

7.4.2.1. METALLIC MATERIALS

 

7.4.2.1.1. STAINLESS STEEL

 

7.4.2.1.1.1 MARKET VALUE (USD MILLION)

7.4.2.1.1.2 MARKET VALUE (UNITS)

7.4.2.1.1.3 AVERAGE SELLING PRICE (USD)

 

7.4.2.1.2. COBALT ALLOY METAL

 

7.4.2.1.2.1 MARKET VALUE (USD MILLION)

7.4.2.1.2.2 MARKET VALUE (UNITS)

7.4.2.1.2.3 AVERAGE SELLING PRICE (USD)

 

7.4.2.1.3. GOLD

 

7.4.2.1.3.1 MARKET VALUE (USD MILLION)

7.4.2.1.3.2 MARKET VALUE (UNITS)

7.4.2.1.3.3 AVERAGE SELLING PRICE (USD)

 

7.4.2.1.4. TANTALUM

 

7.4.2.1.4.1 MARKET VALUE (USD MILLION)

7.4.2.1.4.2 MARKET VALUE (UNITS)

7.4.2.1.4.3 AVERAGE SELLING PRICE (USD)

 

7.4.2.1.5. PLATINUM CHROMIUM

 

7.4.2.1.5.1 MARKET VALUE (USD MILLION)

7.4.2.1.5.2 MARKET VALUE (UNITS)

7.4.2.1.5.3 AVERAGE SELLING PRICE (USD)

 

7.4.2.1.6. NICKEL TITANIUM

 

7.4.2.1.6.1 MARKET VALUE (USD MILLION)

7.4.2.1.6.2 MARKET VALUE (UNITS)

7.4.2.1.6.3 AVERAGE SELLING PRICE (USD)

 

7.4.2.2. POLYMERS BIOMATERIALS

 

7.4.2.2.1. MARKET VALUE (USD MILLION)

7.4.2.2.2. MARKET VALUE (UNITS)

7.4.2.2.3. AVERAGE SELLING PRICE (USD)

 

7.4.2.3. NATURAL BIOMATERIALS

 

7.4.2.3.1. MARKET VALUE (USD MILLION)

7.4.2.3.2. MARKET VALUE (UNITS)

7.4.2.3.3. AVERAGE SELLING PRICE (USD)

 

7.4.3 BY MODE OF DELIVERY

 

7.4.3.1. BALLOON EXPANDABLE STENTS

 

7.4.3.1.1. MARKET VALUE (USD MILLION)

7.4.3.1.2. MARKET VALUE (UNITS)

7.4.3.1.3. AVERAGE SELLING PRICE (USD)

 

7.4.3.2. SELF EXPANDING STENTS

 

7.4.3.2.1. MARKET VALUE (USD MILLION)

7.4.3.2.2. MARKET VALUE (UNITS)

7.4.3.2.3. AVERAGE SELLING PRICE (USD)

 

7.5 VASCULAR CLOSURE DEVICES (VCDS)

 

7.5.1 BY TYPE

 

7.5.1.1. COLLAGEN PLUG-BASED (ANGIO-SEAL)

 

7.5.1.1.1. MARKET VALUE (USD MILLION)

7.5.1.1.2. MARKET VALUE (UNITS)

7.5.1.1.3. AVERAGE SELLING PRICE (USD)

 

7.5.1.2. SEALANT OR GEL BASED DEVICES

 

7.5.1.2.1. MARKET VALUE (USD MILLION)

7.5.1.2.2. MARKET VALUE (UNITS)

7.5.1.2.3. AVERAGE SELLING PRICE (USD)

 

7.5.1.3. COMPRESSION ASSISTED DEVICES

 

7.5.1.3.1. MARKET VALUE (USD MILLION)

7.5.1.3.2. MARKET VALUE (UNITS)

7.5.1.3.3. AVERAGE SELLING PRICE (USD)

 

7.5.1.4. SUTURE BASED (PERCLOSE)

 

7.5.1.4.1. MARKET VALUE (USD MILLION)

7.5.1.4.2. MARKET VALUE (UNITS)

7.5.1.4.3. AVERAGE SELLING PRICE (USD)

 

7.5.1.5. NITINOL CLIP-BASED (STARCLOSE) DEVICES

 

7.5.1.5.1. MARKET VALUE (USD MILLION)

7.5.1.5.2. MARKET VALUE (UNITS)

7.5.1.5.3. AVERAGE SELLING PRICE (USD)

 

7.5.2 BY MODE OF ACTION

 

7.5.2.1. FEMORAL ACCESS 

 

7.5.2.1.1. MARKET VALUE (USD MILLION)

7.5.2.1.2. MARKET VALUE (UNITS)

7.5.2.1.3. AVERAGE SELLING PRICE (USD)

 

7.5.2.2. RADIAL ACCESS

 

7.5.2.2.1. MARKET VALUE (USD MILLION)

7.5.2.2.2. MARKET VALUE (UNITS)

7.5.2.2.3. AVERAGE SELLING PRICE (USD)

 

7.6 INTRAVASCULAR ULTRASOUND (IVUS)

 

7.6.1 MARKET VALUE (USD MILLION)

7.6.2 MARKET VALUE (UNITS)

7.6.3 AVERAGE SELLING PRICE (USD)

7.7 FRACTIONAL FLOW RESERVE (FFR)

 

7.7.1 MARKET VALUE (USD MILLION)

7.7.2 MARKET VALUE (UNITS)

7.7.3 AVERAGE SELLING PRICE (USD)

 

7.8 OPTICAL COHERENCE TOMOGRAPHY (OCT) 

 

7.8.1 MARKET VALUE (USD MILLION)

7.8.2 MARKET VALUE (UNITS)

7.8.3 AVERAGE SELLING PRICE (USD)

 

7.9 ACCESSORIES

 

7.9.1 BALLOON INFLATION DEVICES

 

7.9.1.1. MARKET VALUE (USD MILLION)

7.9.1.2. MARKET VALUE (UNITS)

7.9.1.3. AVERAGE SELLING PRICE (USD)

 

7.9.2 ANGIOPLASTY KITS

 

7.9.2.1. MARKET VALUE (USD MILLION)

7.9.2.2. MARKET VALUE (UNITS)

7.9.2.3. AVERAGE SELLING PRICE (USD)

 

7.9.3 INTRODUCER SHEATHS

 

7.9.3.1. MARKET VALUE (USD MILLION)

7.9.3.2. MARKET VALUE (UNITS)

7.9.3.3. AVERAGE SELLING PRICE (USD)

 

7.9.4 OTHERS

 

8. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY TYPE

 

8.1 OVERVIEW

 

8.2 CONVENTIONAL

 

8.2.1 CORONARY GUIDE WIRES

8.2.2 CATHETERS

8.2.3 CORONARY STENTS

8.2.4 VASCULAR CLOSURE DEVICES (VCDS)

8.2.5 OTHERS

 

8.3 ADVANCED

 

8.3.1 INTRAVASCULAR ULTRASOUND (IVUS)

8.3.2 FRACTIONAL FLOW RESERVE (FFR)

8.3.3 OPTICAL COHERENCE TOMOGRAPHY (OCT) 

9. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY INDICATION

 

9.1 OVERVIEW

9.2 ISCHEMIC HEART DISEASE

9.3 PERCUTANEOUS CORONARY INTERVENTION

9.4 STENT PLACEMENT

9.5 CORONARY THROMBECTOMY

9.6 CONGENITAL HEART ABNORMALITIES

9.7 OTHERS

 

10. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY AGE

 

10.1 OVERVIEW

10.2 ADULT

10.3 PEDIATRIC

10.4 GERIARTIC

 

11. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY END USER

 

11.1 OVERVIEW

 

11.2 HOSPITALS

 

11.2.1 ACUTE CARE HOSPITALS

11.2.2 LONG-TERM CARE HOSPITALS 

 

11.3 CATH LABORATORIES

11.4 AMBULATORY SURGICAL CENTERS

11.5 ACADEMIC & RESEARCH INSTITUTES

11.6 OTHERS

 

12. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY DISTRIBUTION CHANNEL

 

12.1 OVERVIEW

12.2 DIRECT TENDERS

12.3 RETAIL SALES

12.4 OTHERS

 

13. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, BY COUNTRY

GLOBAL INTERVENTIONAL CARDIOLOGY MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

 

13.1 NORTH AMERICA

 

13.1.1 U.S.

13.1.2 CANADA

13.1.3 MEXICO

13.2 EUROPE

 

13.2.1 GERMANY

13.2.2 U.K.

13.2.3 ITALY

13.2.4 FRANCE

13.2.5 SPAIN

13.2.6 RUSSIA

13.2.7 SWITZERLAND

13.2.8 TURKEY

13.2.9 BELGIUM

13.2.10 NETHERLANDS

13.2.11 DENMARK

13.2.12 SWEDEN

13.2.13 POLAND

13.2.14 NORWAY

13.2.15 FINLAND

13.2.16 REST OF EUROPE

 

13.3 ASIA-PACIFIC

 

13.3.1 JAPAN

13.3.2 CHINA

13.3.3 SOUTH KOREA

13.3.4 INDIA

13.3.5 SINGAPORE

13.3.6 THAILAND

13.3.7 INDONESIA

13.3.8 MALAYSIA

13.3.9 PHILIPPINES

13.3.10 AUSTRALIA

13.3.11 NEW ZEALAND

13.3.12 VIETNAM

13.3.13 TAIWAN

13.3.14 REST OF ASIA-PACIFIC

 

13.4 SOUTH AMERICA

 

13.4.1 BRAZIL

13.4.2 ARGENTINA

13.4.3 REST OF SOUTH AMERICA 

13.5 MIDDLE EAST AND AFRICA

 

13.5.1 SOUTH AFRICA

13.5.2 EGYPT

13.5.3 BAHRAIN

13.5.4 UNITED ARAB EMIRATES

13.5.5 KUWAIT

13.5.6 OMAN

13.5.7 QATAR

13.5.8 SAUDI ARABIA

13.5.9 REST OF MEA

 

13.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES 

 

14. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, SWOT AND DBMR ANALYSIS

 

15. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, COMPANY LANDSCAPE

 

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15.5 MERGERS & ACQUISITIONS

15.6 NEW PRODUCT DEVELOPMENT & APPROVALS

15.7 EXPANSIONS

15.8 REGULATORY CHANGES

15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

 

16. GLOBAL INTERVENTIONAL CARDIOLOGY MARKET, COMPANY PROFILE

 

16.1 ABBOTT LABORATORIES

 

16.1.1 COMPANY OVERVIEW

16.1.2 REVENUE ANALYSIS

16.1.3 GEOGRAPHIC PRESENCE

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPEMENTS

 

16.2 B. BRAUN MELSUNGEN AG

 

16.2.1 COMPANY OVERVIEW

16.2.2 REVENUE ANALYSIS

16.2.3 GEOGRAPHIC PRESENCE

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPEMENTS

16.3 BIOSENSORS INTERNATIONAL GROUP LTD

 

16.3.1 COMPANY OVERVIEW

16.3.2 REVENUE ANALYSIS

16.3.3 GEOGRAPHIC PRESENCE

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPEMENTS

 

16.4 BIOTRONIK

 

16.4.1 COMPANY OVERVIEW

16.4.2 REVENUE ANALYSIS

16.4.3 GEOGRAPHIC PRESENCE

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPEMENTS

 

16.5 BD

 

16.5.1 COMPANY OVERVIEW

16.5.2 REVENUE ANALYSIS

16.5.3 GEOGRAPHIC PRESENCE

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPEMENTS

 

16.6 BOSTON SCIENTIFIC

 

16.6.1 COMPANY OVERVIEW

16.6.2 REVENUE ANALYSIS

16.6.3 GEOGRAPHIC PRESENCE

16.6.4 PRODUCT PORTFOLIO

16.6.5 RECENT DEVELOPEMENTS

 

16.7 CARDINAL HEALTH

 

16.7.1 COMPANY OVERVIEW

16.7.2 REVENUE ANALYSIS

16.7.3 GEOGRAPHIC PRESENCE

16.7.4 PRODUCT PORTFOLIO

16.7.5 RECENT DEVELOPEMENTS

 

16.8 COOK MEDICAL INC.

 

16.8.1 COMPANY OVERVIEW

16.8.2 REVENUE ANALYSIS

16.8.3 GEOGRAPHIC PRESENCE

16.8.4 PRODUCT PORTFOLIO

16.8.5 RECENT DEVELOPEMENTS

16.9 MICROPORT SCIENTIFIC CORP.

 

16.9.1 T COMPANY OVERVIEW

16.9.2 REVENUE ANALYSIS

16.9.3 GEOGRAPHIC PRESENCE

16.9.4 PRODUCT PORTFOLIO

16.9.5 RECENT DEVELOPEMENTS

 

16.10 TELEFLEX INC. 

 

16.10.1 COMPANY OVERVIEW

16.10.2 REVENUE ANALYSIS

16.10.3 GEOGRAPHIC PRESENCE

16.10.4 PRODUCT PORTFOLIO

16.10.5 RECENT DEVELOPEMENTS

 

16.11 MEDTRONIC INC.

 

16.11.1 COMPANY OVERVIEW

16.11.2 REVENUE ANALYSIS

16.11.3 GEOGRAPHIC PRESENCE

16.11.4 PRODUCT PORTFOLIO

16.11.5 RECENT DEVELOPEMENTS

 

16.12 TERUMO MEDICAL CORPORATION

 

16.12.1 COMPANY OVERVIEW

16.12.2 REVENUE ANALYSIS

16.12.3 GEOGRAPHIC PRESENCE

16.12.4 PRODUCT PORTFOLIO

16.12.5 RECENT DEVELOPEMENTS

 

16.13 HITACHI MEDICAL SYSTEMS

 

16.13.1 COMPANY OVERVIEW

16.13.2 REVENUE ANALYSIS

16.13.3 GEOGRAPHIC PRESENCE

16.13.4 PRODUCT PORTFOLIO

16.13.5 RECENT DEVELOPEMENTS

 

16.14 SIEMENS HEALTHINEERS

 

16.14.1 COMPANY OVERVIEW

16.14.2 REVENUE ANALYSIS

16.14.3 GEOGRAPHIC PRESENCE

16.14.4 PRODUCT PORTFOLIO

16.14.5 RECENT DEVELOPEMENTS 

16.15  KONINKLIJKE PHILIPS N.V

 

16.15.1 COMPANY OVERVIEW

16.15.2 REVENUE ANALYSIS

16.15.3 GEOGRAPHIC PRESENCE

16.15.4 PRODUCT PORTFOLIO

16.15.5 RECENT DEVELOPEMENTS 

 

16.16 GE HEALTHCARE

 

16.16.1 COMPANY OVERVIEW

16.16.2 REVENUE ANALYSIS

16.16.3 GEOGRAPHIC PRESENCE

16.16.4 PRODUCT PORTFOLIO

16.16.5 RECENT DEVELOPEMENTS 

 

16.17 CARESTREAM HEALTH INC.

 

16.17.1 COMPANY OVERVIEW

16.17.2 REVENUE ANALYSIS

16.17.3 GEOGRAPHIC PRESENCE

16.17.4 PRODUCT PORTFOLIO

16.17.5 RECENT DEVELOPEMENTS 

 

16.18 SHIMADZU MEDICAL

 

16.18.1 COMPANY OVERVIEW

16.18.2 REVENUE ANALYSIS

16.18.3 GEOGRAPHIC PRESENCE

16.18.4 PRODUCT PORTFOLIO

16.18.5 RECENT DEVELOPEMENTS 

 

16.19 CANON MEDICAL SYSTEMS CORPORATION

 

16.19.1 COMPANY OVERVIEW

16.19.2 GEOGRAPHIC PRESENCE

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPEMENTS 

 

16.20 CAMPO IMAGING

 

16.20.1 COMPANY OVERVIEW

16.20.2 REVENUE ANALYSIS

16.20.3 GEOGRAPHIC PRESENCE

16.20.4 PRODUCT PORTFOLIO

16.20.5 RECENT DEVELOPEMENTS 

16.21 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD

 

16.21.1 COMPANY OVERVIEW

16.21.2 REVENUE ANALYSIS

16.21.3 GEOGRAPHIC PRESENCE

16.21.4 PRODUCT PORTFOLIO

16.21.5 RECENT DEVELOPEMENTS 

 

16.22 GALT MEDICAL CORP.

 

16.22.1 COMPANY OVERVIEW

16.22.2 GEOGRAPHIC PRESENCE

16.22.3 PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPEMENTS 

 

16.23 SHENZHEN BASDA MEDICAL APPARATUS CO.,LTD

 

16.23.1 COMPANY OVERVIEW

16.23.2 REVENUE ANALYSIS

16.23.3 GEOGRAPHIC PRESENCE

16.23.4 PRODUCT PORTFOLIO

16.23.5 RECENT DEVELOPEMENTS 

 

16.24 CORDIS

 

16.24.1 COMPANY OVERVIEW

16.24.2 REVENUE ANALYSIS

16.24.3 GEOGRAPHIC PRESENCE

16.24.4 PRODUCT PORTFOLIO

16.24.5 RECENT DEVELOPEMENTS 

 

16.25 ANDRATEC 

 

16.25.1 COMPANY OVERVIEW

16.25.2 REVENUE ANALYSIS

16.25.3 GEOGRAPHIC PRESENCE

16.25.4 PRODUCT PORTFOLIO

16.25.5 RECENT DEVELOPEMENTS 

 

16.26 STRON MEDICAL

 

16.26.1 COMPANY OVERVIEW

16.26.2 REVENUE ANALYSIS

16.26.3 GEOGRAPHIC PRESENCE

16.26.4 PRODUCT PORTFOLIO

16.26.5 RECENT DEVELOPEMENTS 

16.27 BALTON SP. Z O.O.

 

16.27.1 COMPANY OVERVIEW

16.27.2 REVENUE ANALYSIS

16.27.3 GEOGRAPHIC PRESENCE

16.27.4 PRODUCT PORTFOLIO

16.27.5 RECENT DEVELOPEMENTS 

 

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS

 

17. CONCLUSION

 

18. QUESTIONNAIRE

 

19. ABOUT DATA BRIDGE MARKET RESEARCH

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Interventional Cardiology Market will be worth USD 23.61 billion by 2030.
The Interventional Cardiology market growth rate is 7.1% during the forecast period.
The Increasing prevalence of cardiovascular diseases, Preference for minimally invasive procedures, and Technological advancements are the Growth Drivers of the Interventional Cardiology Market.
The device type and end-user are the factors on which the Interventional Cardiology Market research is based
The Abbott announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations and Abbott announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations are the latest developments in the Interventional Cardiology Market.

Industry Related Reports

Testimonial